Close Menu
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Seoul Daily NewsSeoul Daily News
    • Home
    • Contact Us
    Seoul Daily NewsSeoul Daily News
    Home » Innovative experimental malaria drug based on antibodies discovered
    Featured News

    Innovative experimental malaria drug based on antibodies discovered

    November 1, 2022
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    A new study in Africa has found that a one-time dose of an experimental drug protects adults against malaria for at least six months. In 2020, malaria killed more than 620,000 people and sickened 241 million, mostly children under 5. There is a malaria vaccine being rolled out by the World Health Organization for children, but it is only 30% effective and requires four doses.

    Innovative experimental malaria drug based on antibodies discoveredIn this new study, people received a large dose of lab-made malaria-fighting antibodies instead of relying on the immune system to make enough of those same infection-blockers after vaccination, reported the Associated Press (AP). “There are not enough people protected by the vaccine available,” said Kassoum Kayentao, a researcher from the University of Sciences, Techniques and Technologies in Bamako, Mali.

    In those villages, people are bitten by infected mosquitoes on average twice a day during malaria season, according to other research. Experimental antibody, developed by researchers at the US National Institutes of Health, was delivered by IV. In the meantime, an easy-to-administer shot version from the same scientists is in early testing in infants, children, and adults.

    Research presented at a medical meeting in Seattle was published Monday in the New England Journal of Medicine. In order to work, the antibody breaks the life cycle of the parasite, which is spread through mosquito bites. It targets immature parasites before they mature and multiply in the liver. An antibody taken from a volunteer who received a malaria vaccine was used to develop it.

    It involved 330 adults in Mali who received either a dummy infusion or two different antibody doses. Every two weeks for 24 weeks, all were tested for malaria infection. Treatment was provided to anyone who became ill. A blood test detected infections in 20 people who received the higher dose, 39 people who received the lower dose, and 86 people who received the placebo. Compared to the placebo, the higher dose was 88% effective. There was a 75% effectiveness rate for the lower dose.

    During a malaria season, protection might last for several months. In the future, it could be used in conjunction with other malaria prevention methods, such as malaria pills, mosquito nets, and vaccinations. According to one estimate, lab-made antibodies could be given for as little as $5 per child per malaria season.

    Related Posts

    AsiaWire Connects Asia’s Media Diversity Through Technology

    October 20, 2026

    STS Digital Named North America’s Best Digital Assets Trading Platform/Venue by Euromoney

    October 16, 2026

    STS Digital Named Digital Asset Provider of the Year by FOW

    September 25, 2026

    Papa Johns teams up with Disney and Pixar for Toy Story 5

    August 7, 2026

    Silver tumbles as COMEX margins rise and volatility spikes

    February 14, 2026

    UAE and Egypt reaffirm ties as leaders meet in Abu Dhabi

    February 10, 2026
    Latest News

    WHO calls for stronger Ebola surveillance in DR Congo

    October 24, 2026

    India and Poland agree to double bilateral trade by 2030

    October 24, 2026

    Russia-Oman trade jumps 22-fold to $1.5 billion, Shoigu says

    October 23, 2026

    Magnitude 7 earthquake in Tibet kills 16 and injures dozens

    October 23, 2026
    © 2026 Seoul Daily News | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.